October 3, 2011
In a report issued on September 16, Barclays Capital Securities upwardly revised its sales forecast for Mitsubishi Tanabe Pharma Corporation’s (MTPC) hepatitis C treatment Telavic (telaprevir) and raised the company’s investment outlook and target share price. The revision was based...read more